Blood cancers

Episode 2: The changing therapeutic landscape for R/R CLL, with Dr Phillip Thompson

Sponsored by Janssen-Cilag Pty Ltd

In the second part of this podcast, haematologist and clinical researcher Dr Phillip Thompson talks about the rapidly evolving area of treatment for relapsed/refractory CLL after chemo-immunotherapy. Dr ThompsonĀ  says it is important to re-evaluate a person’s genomic characteristics after a relapse and the overall approach is to use novel agents rather than repeat chemo-immunotherapy. ...

Already a member?

Login to keep reading.

© 2021 the limbic